Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In a phase 3 trial, tisotumab vedotin showed a median overall survival of 11.5 months compared to 9.5 months with standard chemotherapy in patients with recurrent cervical cancer, representing a 30% reduction in the risk of death.
Oncology, Medical July 16th 2024
Northwestern Medicine
This refined surgical technique for robotic-assisted laparoscopic radical prostatectomy focuses on preserving vital supportive structures while effectively removing the prostate, potentially enhancing post-operative outcomes.
Recent research suggests that transperineal prostate biopsies can be safely performed without antibiotics, potentially offering an alternative to traditional transrectal biopsies for cancer detection and monitoring.
Epoch Health
This study provides concrete data on the proportion of cancer cases attributable to modifiable risk factors, offering a powerful tool for patient education and risk reduction strategies.
Hematology/Oncology July 16th 2024
Oncology News Central (ONC)
The pressure to publish extensively, attend numerous conferences, and navigate academic tribalism is causing young oncologists to reconsider careers in academia, potentially impacting the future of cancer research and treatment.
Rare Disease Advisor
Dedifferentiated liposarcoma, a malignancy with significant metastatic potential, requires precise diagnosis through MRI, PET scans, and genetic testing. MDM2 and CDK4 are pivotal markers for distinguishing DDL from other sarcomas.
Oncology, Medical July 2nd 2024